ABCG2 and cancer: Nanomedicines are increasingly being developed to overcome MDR as they can enter cancer cells via endocytosis, thus bypassing ABC transporters and ultimately leading to increased intracellular concentrations of cancer-killing drugs (Yan et al., 2010).